* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download The Molecular and Neuroanatomical Basis for Estrogen Effects in
Synaptic gating wikipedia , lookup
Neuroeconomics wikipedia , lookup
Causes of transsexuality wikipedia , lookup
Subventricular zone wikipedia , lookup
Psychoneuroimmunology wikipedia , lookup
Neurogenomics wikipedia , lookup
Neurolinguistics wikipedia , lookup
Neuroinformatics wikipedia , lookup
Nervous system network models wikipedia , lookup
Brain morphometry wikipedia , lookup
Selfish brain theory wikipedia , lookup
Optogenetics wikipedia , lookup
Limbic system wikipedia , lookup
Environmental enrichment wikipedia , lookup
Single-unit recording wikipedia , lookup
Brain Rules wikipedia , lookup
Biochemistry of Alzheimer's disease wikipedia , lookup
History of neuroimaging wikipedia , lookup
Neurophilosophy wikipedia , lookup
Neuroplasticity wikipedia , lookup
Stimulus (physiology) wikipedia , lookup
Cognitive neuroscience wikipedia , lookup
Activity-dependent plasticity wikipedia , lookup
Circumventricular organs wikipedia , lookup
Impact of health on intelligence wikipedia , lookup
Neuropsychology wikipedia , lookup
Haemodynamic response wikipedia , lookup
Holonomic brain theory wikipedia , lookup
Signal transduction wikipedia , lookup
Channelrhodopsin wikipedia , lookup
Metastability in the brain wikipedia , lookup
Aging brain wikipedia , lookup
Endocannabinoid system wikipedia , lookup
Hypothalamus wikipedia , lookup
Molecular neuroscience wikipedia , lookup
Neuroanatomy wikipedia , lookup
0021-972X/99/$03.00/0 The Journal of Clinical Endocrinology & Metabolism Copyright © 1999 by The Endocrine Society Vol. 84, No. 6 Printed in U.S.A. CLINICAL REVIEW 108 The Molecular and Neuroanatomical Basis for Estrogen Effects in the Central Nervous System BRUCE S. MCEWEN Harold and Margaret Milliken Hatch Laboratory of Neuroendocrinology, Rockefeller University, New York, New York 10021 With increasing life expectancy during the 20th century, women are likely to live a substantial part of their lives in a state of estrogen deficiency. Hot flushes are for many women the most dramatic and noticeable consequence of loss of ovarian hormones. Loss of bone calcium and osteoporosis, developing much more gradually, is another consequence that has led many women to take estrogen replacement therapy (ERT) at the menopause. Likewise, the loss of protection of the coronary arteries, leading postmenopausal women to increased risk for cardiovascular disease, is another result of estrogen deficiency that has reinforced the value of ERT. Yet, it is only quite recently that medical science has recognized that the brain is one of the organs of the body that suffers from the loss of this circulating hormone. This has happened despite studies over more than 30 yr indicating that estrogens target the brain of experimental animals (for summary, see Ref. 1). However, most of the animal studies have focused on estrogen actions on the hypothalamus affecting ovulation and reproductive behavior, and only recently has it become apparent that estrogens exert many actions outside of the reproductive function, including actions on brain areas that are important for learning and memory, emotions and affective state, as well as motor coordination and pain sensitivity. Indeed, some women experience at surgical or natural menopause difficulties in remembering names and other information important for daily life as well as deficits in fine motor coordination and reaction times and feelings of depression and anxiety (2). These effects reflect the actions of estrogens on a large number of brain areas outside of the hypothalamus. The problem in these brain regions has been to recognize the receptors and mechanisms by which estrogens produce their effects. This brief review will focus on two aspects: first, the cellular and molecular mechanisms by which estrogens produce their diverse effects on the brain; and second, the brain regions and cell types in which estrogens produce their effects, emphasizing new knowledge regarding estrogen actions outside of the hypothalamus and pituitary gland. Finally, a brief disReceived January 27, 1999. Revision received March 10, 1999. Accepted March 15, 1999. Address all correspondence and requests for reprints to: Dr. Bruce S. McEwen, Laboratory of Neuroendocrinology, Rockefeller University, 1230 York Avenue, New York, New York 10021. E-mail:mcewen@ rockvax.rockefeller.edu. cussion will summarize the potential clinical applications of this information, particularly in relation to cognitive function and dementia. Historical overview In the early 1960s, putative DNA-binding estrogen receptors (ERs) were identified as proteinaceous binding sites for tritiated estradiol in the tissue cytosol and cell nuclear compartment (3). Found initially in reproductive tract, putative ERs were subsequently identified by in vitro cytosol binding and in vivo uptake and cell nuclear retention in the pituitary gland and hypothalamus (1). At first, only ERs in the hypothalamus and pituitary gland were studied because they were the most obvious and also the most obviously related to estrogen actions on reproduction. Gradually, however, nerve cells containing putative ERs were recognized in brain regions such as the hippocampus, cerebral cortex, midbrain, and brain stem. The introduction of antibodies to ERs and the cloning of ERs permitted more direct measurements of the receptor themselves or their messenger ribonucleic acids (mRNAs) by immunocytochemistry and in situ hybridization histochemistry, and these newer tools generally confirmed the older localization of ERs based upon tritiated estrogen binding and steroid autoradiography. The classical intracellular ER is called the ERa (see Ref. 2 for summary). Recently, a new form of the intracellular ER, the ERb, was cloned, and mapping studies are underway in the brain and other tissues and organs, as summarized below. The localization of this receptor to new cell types will undoubtedly extend the list of tissue, organs, and brain regions that are capable of responding to estrogens with a regulation of gene expression. At the same time that progress with intracellular ERs has accelerated, other investigations of the functional effects of estrogens on nerve cell activity and neuroprotection have uncovered rapid actions of these hormones that cannot involve activation or repression of gene expression, because of either their extreme rapidity or their structure-activity profile in relation to the specificity of known intracellular ERs. These nongenomic actions of estrogens operate in many cases on the cell surface and affect the excitability of nerve cells and smooth muscle cells and the movement of the sodium, potassium and calcium ions that create a nerve impulse and modulate the internal state of neurons. However, we know very little about the molecular characteristics and the mech- 1790 CLINICAL REVIEW anism of action of these nongenomic receptors in cell membranes. Nevertheless, the effects that they mediate are of sufficient interest to make them an essential component of a review of estrogen action in brain. We shall now discuss these issues in greater depth, using a figure and a number of summary tables to cover material that the reader may find in more detail in another review (2). ERs and actions in the central nervous system The variety of estrogen effects has been expanded to include rapid actions on excitability of neuronal and pituitary cells, the activation of cAMP- and mitogen-activated protein kinase (MAP kinase) pathways, effects on calcium channels and calcium ion entry, and protection of neurons from damage by excitotoxins and free radicals (Table 1 and Fig. 1). These estrogen actions occur through at least two types of intracellular receptors as well as a number of other mechanisms involving receptors that have not been characterized. Indeed, for a number of processes, there are conflicting reports, based upon estrogen structure-activity studies and the actions of estrogen antagonists, that intracellular receptors may not be involved. Thus, as summarized in Table 1, for estrogen actions on some aspects of calcium homeostasis, certain aspects of second messenger systems and some features of neuroprotection, a novel receptor mechanism is implicated, in which stereospecificity for 17b- over 17a-estradiol is replaced by a broader specificity for the 3-hydroxyl group on the A ring. Such findings suggest that there are novel receptor mechanisms not involving the classical intracellular ER. However, before discussing these receptors, we shall consider the intracellular ER. Intracellular ERs ERa shows a characteristic distribution in the nervous system, with high levels in the pituitary, hypothalamus, the hypothalamic preoptic area and amygdala and much lower levels, and a more scattered distribution, in other brain regions. The discovery and cloning of ERb (4 – 6) radically changed the view of estrogen action and provided, among other things, a basis for understanding how the knockout of ERa (aERKO) (7, 8) could have resulted in a viable organism 1791 and in the continued actions of estrogens on many tissues. The deletion of the ERb gene was described recently (9), and bERKO animals are remarkably normal and are even able to reproduce, although they show some reduction in litter size. This is in contrast to the aERKO mice, which are sterile and show altered sexual and other behaviors (see Ref. 2 for summary). Measurements of messenger RNA (mRNA) for ERa and ERb reveal distributions in the body that differ quite markedly from each other, with moderate to high expression of ERa mRNA in pituitary, kidney, epididymus, and adrenal; moderate to high expression of ERb mRNA in prostate, lung, bladder, and brain; and overlapping high expression in ovary, testis, and uterus (10). Isoforms of ERb have been identified (see Ref. 2 for summary). The best characterized of these variants has been termed ERb2. Compared to the originally designated ERb1, this isoform has a lower affinity for estrogens (11), presumably due to an 18-amino acid insertion in the ligand-binding domain (12). In brain, the distribution of ERa is well established, but there is less certainty and more controversy surrounding the localization of ERb. The autoradiographic maps of [3H]estradiol uptake and retention in brain (13, 14) are presumed to reflect binding to all forms of the ER, particularly the ERa and the ERb1 isoforms, which have similar affinities for 17b-estradiol (10). In situ hybridization data suggest widespread distribution of ERb mRNA throughout much of the brain, including olfactory bulbs, cerebellum, and cerebral cortex (15, 16), whereas results from immunocytochemical studies for ERb indicate a more restricted localization of detectable protein, although the antisera that are currently available do not always provide specific signals in some brain areas (see Ref. 2 for discussion). Thus, it remains a likely, but unproved, assumption that the presence of ERb mRNA indicates the presence of some functional ERb receptor protein, even if the [3H]estradiol autoradiography, mentioned above, has shown very little in the way of functional ER in some of the brain regions where ERb mRNA is expressed. The possible presence of low levels of intracellular ER, not detectable by either autoradiography or immunocytochemistry, remains one of the thorniest issues affecting TABLE 1. Actions of estrogens related to excitability and cell membrane events Membrane binding sites: identified but not well characterized in pituitary, liver, and endometrium, but not in brain; some membrane sites may be related to intracellular ER (23, 24). Genomic effects on membrane events, e.g.: induction of the MINK potassium channel in pituitary via genomic mechanism (58); calcium channel expression in pituitary and hippocampus (59). Apparent nongenomic actions, e.g.: rapid excitation of electrical activity in cerebellum, hippocampus, striatum, and cerebral cortex; effects occur within seconds and are unlikely to involve a transcriptional activation (60). Second messenger activation CREB phosphorylation: genomic vs. nongenomic mechanism unclear (25, 26). MAP kinase activation: possible novel receptor pathway or involvement of classical ER in a novel signaling pathway (27). Calcium homeostasis Rapid actions: 17bE is more potent, but tamoxifen is an agonist on Ca21 currents (61). Rapid actions: 17aE is as potent as 17bE on calcium entry (62). Possible genomic actions: delayed and sustained increase in Ca channel activity (59). Neuroprotection Rapid actions: 17aE is as potent as 17bE vs. oxidative damage (63). Genomic actions: 17bE is more potent; antiestrogen blockade (64). Examples are provided for each topic. For detailed summary, see Ref. 2. Note that these estrogen actions are not mutually exclusive, but may represent different end points of interacting intracellular signaling cascades. 1792 MCEWEN FIG. 1. Schematic diagram of intracellular estrogen action via ERa and ERb as well as possible cell surface effects of putative membrane ERs that produce neuroprotection (top) or affect intracellular signaling (bottom) via the cAMP and MAP kinase pathways. Top panel, Estradiol exerts its effects intracellularly via two principal receptor types, ERa and ERb, and these are characterized by a distinct specificity for 17a-estradiol over 17b-estradiol. Estrogens also exert neuroprotective effects in part via a mechanism in which 17a-estradiol has equal or greater potency than 17b-estradiol. Bottom panel, Estradiol acts either via cell surface receptors or an intracellular ER to activate two different second messenger pathways, one involving the MAP kinase cascade and the other involving cAMP. Both pathways result in activation of gene transcription via at least three possible response elements: cAMP response element, steroid response element, and AP-1. Note that in the case of intracellular second messengers, there is some uncertainty concerning the involvement of ERa and ERb in the signaling process vs. the roles of other, as yet uncharacterized, receptors (see text). AC, Adenylate cyclase; CREB-P, phosphorylated form of cAMP response element-binding protein; ras, ras oncogene; MAPK, MAP kinase; MAPKK, MAP kinase kinase; fos-jun, Fos-Jun heterodimer. This figure was reprinted from Ref. 2; please see this reference for details. progress in understanding the molecular mechanisms of estrogen action in the nervous system. ERa and ERb are similar not only in affinity for a number of estrogens and estrogen antagonists (10), but also in their ability to regulate genes in which the estrogen response element is the primary site of interaction (17). The major differences between ERa and ERb concern their ability to regulate transcription via the activating protein-1 (AP-1) response element. With AP-1, 17b-estradiol activated transcription with ERa, whereas it failed to activate transcription with ERb; in contrast, with AP-1, antiestrogens activated JCE & M • 1999 Vol 84 • No 6 transcription with ERb as well as with ERa (17). ERa and ERb can form heterodimers when expressed in the same cells, thus giving rise to additional possible variants as far as gene regulation (6). To date, colocalization of ERa with ERb has been demonstrated in the hypothalamic preoptic area, bed nucleus of the stria terminalis, and medial amygdaloid nucleus (18), and the two ER forms probably coexist in cells of other brain regions. It has been known for some time that estrogen antagonists produced agonist-like effects on some parameters in the brain and antagonize other estrogen actions, and the heterogeneity of these effects has implications for the therapeutic use of these substances. This has been studied in some detail for one antagonist, CI-628, a tamoxifen-like estrogen antagonist. The antagonistic effects of CI-628 were first seen by its blockade of estrogen induction of both progestin receptors and lordosis behavior (19, 20), whereas the agonist-like effects of CI-628 were seen for induction of choline acetyltransferase, a key enzyme in acetylcholine formation, in basal forebrain and repression of type A monoamine oxidase in amygdala (21). Recently, CI-628 was shown to block estrogen-induced synapse formation in the hippocampus (see below) without having any agonist-like effects (22). One important implication of these findings is that nonsteroidal antiestrogens, such as CI-628, and possibly also related compounds, such as tamoxifen and raloxifene, will not have uniformly agonistic or antagonistic effects on the diversity of actions that estrogens normally produce in the brain. This has implications for the therapeutic applications of such agents and requires a careful study of the actions of these agents on each end point of estrogen action and on integrative neural processes, such as cognition and affective state, in the event that these substances may be antagonistic to estrogens on some processes and exert estrogen-like effects on others. At the same time, the diverse actions of estrogens and estrogen antagonists in brain must be explored in terms of the emerging molecular framework of ERs and response elements, as described above. Novel estrogen actions Membrane ERs have been reported on pituitary, uterine, ovarian granulosa cell, and liver cell membranes, but these have been only partially characterized in binding studies and have not yet been shown to be linked to signal transduction mechanisms (Table 1) (see Ref. 2 for review). Whereas some of these receptors have a specificity for estrogens that differs from that of the intracellular ER, there is evidence (23, 24) that a portion of the intracellular ER can be expressed on the surface of some cells and participate in second messengerrelated effects. Besides the binding of estrogens to cell surface sites or the expression of ER on the membrane, there are reported effects of estrogens on neuronal excitability and second messenger systems that have been difficult to connect with either novel receptor mechanisms or genomic receptors. One reason for these difficulties is a lack, in many cases, of structure-activity studies that would rule in or rule out the participation of intracellular ER. However, in a few cases where such studies have been carried out, there is evidence for novel types of receptors with a pattern of specificity that CLINICAL REVIEW does not discriminate between 17a- and 17b-estradiol (see Table 1 and Fig. 1) (2). Noteworthy among these novel actions of estrogens is the activation of phosphorylation of the transcription regulator, cAMP response element-binding protein (25, 26), and of the MAP kinase pathway (27), which represent novel ways in which estrogens can interact with signaling pathways involving cell surface receptors and thereby participate in cellular events also regulated by growth factors and neurotransmitters. These processes (summarized in Table 1 and Fig. 1) are often interrelated at the level of intracellular signaling, and thus, studies of these individual estrogen effects may some day converge when more is known about each of the mechanisms. Also important, but equally puzzling for lack of mechanistic details, are the novel ways in which estrogenic compounds protect nerve cells from damage by excitotoxins and free radicals (Table 1) (see Ref. 2 for review). In this realm, there are neuroprotective effects that are mediated via classical genomic receptors that can be blocked by estrogen antagonists, but there are also other actions that are not blocked by estrogen antagonists and which appear to involve a novel mechanism in which 17a-estradiol is as potent as 17b-estradiol. These actions of estrogens appear to reduce the production or actions of free radicals in cause cell damage and promoting cell death through apoptosis (for examples, see Table 1). Estrogen actions throughout the central nervous system We now know that ovarian steroids have numerous effects on the brain throughout life, beginning during gestation and 1793 continuing on into senescence. Estrogens participate in the sexual differentiation of the brain during early embryonic or neonatal life, and these effects undoubtedly involve the intracellular ERs described above. The process of sexual differentiation involves the secretion of testosterone in fetal or early neonatal life and the actions of testosterone, either through androgen receptors or via aromatization to estrogen, in the defeminization and masculinization of brain structures and function (28, 29). Although initially believed to be confined to the hypothalamus, structural and functional sex differences have been found in higher cognitive centers and in sensory and autonomic ganglia as well as in structures of the limbic system of the brain, midbrain, brain stem, and basal forebrain structures (see Ref. 2 for review). Estrogens affect areas of the brain that are not primarily involved in reproduction, such as the basal forebrain cholinergic system, hippocampus, cerebral cortex, caudate-putamen, midbrain raphe and brain stem locus coeruleus, and spinal cord (Table 2). These systems are involved in a variety of estrogen actions on mood, locomotor activity, pain sensitivity, vulnerability to epilepsy, and attentional mechanisms and cognition (Table 3; in each of these tables, key examples are given with references). Despite the paucity of ERa outside the hypothalamus, hypothalamic preoptic region, and amygdala, estrogens have effects on many other brain regions and neurochemical systems involved in a host of nonreproductive brain functions. The expression of ERb mRNA in many of these brain regions has raised the possibility that functional ER may be expressed in these brain areas (see discussion above). At the same time, the presence of a few ERa-containing nerve cells TABLE 2. Brain targets of estrogen (E) action Basal forebrain cholinergic system: E up-regulated cholinergic markers and NGF receptors, promoting neuronal survival; sex differences programmed during early development. ERT is an enhancer of the efficacy of tacrine in treatment of cognitive function in dementia (49). Midbrain serotonergic system: E regulates tryptophan hydroxylase, serotonin transporters, and certain 5HT receptor subtypes; sex differences in progestin receptor expression and in 5HT turnover (37). ERT is antidepressant and a facilitator of antidepressant actions of SSRIOs (65). Midbrain and hypothalamic dopamine system and projections: Incertohypothalamic dopamine neurons show developmentally programmed sex differences in neuron number and function; PRL and E, via intracellular ER regulate turnover of dopamine in hypothalamic nuclei. Nigrostriatal and mesolimbic dopamine systems—no known intracellular ER; yet, E facilitates amphetamine- or apomorphinestimulated dopamine release and locomotor activity in rats. In striatum, with males being less responsive to E, there are 4 types of evidence for E actions not involving the intracellular ER: 1) lack of intracellular ER in striatum; 2) rapidity of E effects; 3) pharmacological profile of E action, particularly the ineffectiveness of diethylstilbestrol; and 4) the ability of E conjugated to BSA to mimic effects of free E. One possible explanation is the action of E to reduce L-type calcium channel activity in striatal neurons via a G protein-coupled receptor (61). Brain stem catecholaminergic systems: E regulates tyrosine hydroxylase gene and immediate early gene expression, apparently via intracellular ER. E treatment increases galanin mRNA in some neurons, and this may affect noradrenergic tone by reducing noradrenaline release (66). Hippocampus: E induces de novo synapse formation on pyramidal neurons, involving the participation of NMDA receptors. E treatment transiently down-regulates GABA and BDNF activity in interneurons by a mechanism that is blocked by antiestrogens in a manner that is consistent with a key role for intracellular ER in inhibitory interneurons. See Refs. 67–70 and 2 for review. Spinal cord: sex differences and estrogen modulation of nociception in humans (Refs. 71, 72). Sex differences in analgesia have been reported in mice along with sex-specific effects of E on a form of nonopioid analgesia (73). QTL mapping led to the identification of a female-specific QTL on chromosome 8 (74). This female-specific mechanism, which is sensitive to E modulation, is consistent with a gene that is turned off by testosterone exposure during sexual differentiation (75). Glial cells: E regulates specific genes such as glial fibrillary acidic protein and apolipoprotein E within astrocytes and microglia via intracellular ER. E regulates morphology of astrocytes in hypothalamus and hippocampus, and these changes may reflect a role of glial cells in normal synaptic plasticity as well as lesion-induced plasticity. Cerebral vasculature: Some intracellular ER are expressed in CNS endothelia (76), and E regulates glucose utilization, possibly by inducing glucose transporter 1 in the endothelial cells of the blood-brain barrier (77). This summary is confined to the extrahypothalamic targets for estrogen action, with the exception of the incertohypothalamic dopamine system. For a detailed summary, including a discussion of expression of ER subtypes, see Ref. 2. SSRI, Serotonin reuptake inhibitors; BDNF, brain-derived neurotropic factor; QTL, quantitative trait locus. 1794 MCEWEN JCE & M • 1999 Vol 84 • No 6 TABLE 3. Gonadal hormone effects on clinically relevant nonreproductive functions Affective state and mood: estrogens affect the serotonergic, noradrenergic, dopaminergic, and cholinergic systems, all of which play a role in affective state and mood. Two disorders are particularly noteworthy, PMS and depressive illness. For PMS, suppression of ovarian cyclicity reduces mood swings, although specific hormonal mechanisms are not known (78, 79). High doses of estrogens have antidepressant effects in human subjects (80), and estrogen treatment influences the response to antidepressant drugs in animal models (81). Estrogen treatment has been reported to enhance the efficacy of Prozac treatment for depression (65). Cognitive function: estrogens influence short term verbal memory as well as performance on tests of fine motor skills and spatial ability; sex differences exist in humans and animals for strategies used in solving spatial navigation problems (see Discussion and Ref. 32). Dementia: estrogen therapy in open trials has been reported to improve cognitive function in Alzheimer’s disease patients (82) and to prospectively benefit cognitive function in nondemented women (83, 84). There is a reportedly lower prevalence of Alzheimer’s disease as a cause of death in elderly women who receive estrogen replacement therapy postmenopausally (85, 86). Motor coordination and movement disorders: estrogens modulate activity of the cerebellum and the nigostriatal and mesolimbic dopaminergic systems and have effects on normal and abnormal locomotor activity. High levels of estrogens antagonize the dopamine system and are recognized to exacerbate symptoms of Parkinson’s disease, whereas low estrogen levels facilitate dopaminergic function. See dopamine entry in Table 2. Excitability and epilepsy: catamenial epilepsy varies according to the menstrual cycle, with the peak frequency of occurrence corresponding to the lowest ratio of progesterone to estradiol during the cycle. There are at least 3 potential mechanisms: 1) estrogen induction of excitatory synapses in hippocampus, leading to decreased seizure thresholds; 2) progesterone actions via the steroid metabolites, which act via the GABAa receptor to decrease excitability; and 3) hormone actions on the liver to increase clearance rates of antiseizure medication (87, 88). Pain: Recent studies in mice indicate that males and females use functionally distinct pain pathways, and that gonadal steroids, particularly estrogens, play a major role in regulating these pathways (73). See entry under spinal cord in Table 2. For reviews, see Refs. 2 and 89. PMS, Premenstrual syndrome; GABAa, d-aminobutyric acid-a. has led to the discovery, for example in the hippocampus, that these few nerve cells can have powerful transsynaptic effects on neighboring neurons (see below). In addition, the rapidity and structure-activity profile of some of these effects have raised questions about the possible nontraditional and even nongenomic actions of estrogens in some brain regions. Treatment of ovariectomized rats with 17b-estradiol induces certain hippocampal neurons to form new synaptic connections with other nerve cells. These estrogen effects appear to be attributable to intracellular ERs in inhibitory interneurons that can influence thousands of pyramidal neurons in their vicinity, although the role of ERb in synapse formation has not been ruled in or out (see Ref. 2 for summary). Yet, the actions of estrogens in the basal forebrain, corpus striatum, and nucleus accumbens on dopaminergic activity appear to be mediated by membrane actions, as there is no indication for the expression of either ERa or ERb in these brain regions. On the other hand, estrogen actions on cholinergic, noradrenergic, serotonergic, and hypothalamic dopaminergic systems are probably mediated at least in part by known intracellular ERa or ERb that are expressed in these brain areas (see Ref. 2 for summary). The spinal cord also has intracellular ERa and ERb, but the reported effects on nociception and analgesia do not directly relate to those receptor sites in enkephalin-expressing spinal neurons (see Ref. 2 for summary). Estrogen actions on cognitive function and memory processes Among the most novel and fascinating effects of estrogen are those on cognitive function, and there are at least four aspects of estrogen and progesterone action in brain that are especially relevant to memory processes and their alterations during aging and neurodegenerative diseases (for details, see Ref. 2). First, as noted above, studies of female rats show that estrogens and progestins regulate synaptogenesis in the hippocampus, a brain region important in spatial and declara- tive learning and memory. During the estrous cycle of a female rat, these synapses are formed under the influence of estrogens and are then broken down after the proestrus surge of progesterone (30). In ovariectomized rats, formation of new excitatory synapses is induced by estradiol and involves the participation of a neurotransmitter, glutamic acid, acting through NMDA receptors (31); progesterone administration then triggers the disappearance of the newly formed synapses within 12–24 h. Inhibitory interneurons that innervate thousands of adjacent pyramidal neurons express ERa and are the most likely transsynaptic regulator of synapse formation on the pyramidal neurons. Second, there are developmentally programmed sex differences in hippocampal structure that may help to explain differences in the strategies that male and female rats use to solve spatial navigation problems. Males use global spatial cues more effectively than females to locate food in a radial arm maze or to find a hidden platform in a Morris water maze. An analogous sex difference in spatial problem-solving ability is reported in humans (32). During the period of development when testosterone is elevated in the male, aromatase activity and ERs are transiently expressed in hippocampus (33, 34), and recent data on behavior and synapse induction strongly suggest that this pathway is involved in the masculinization or defeminization of hippocampal structure and function (35, 36). Third, ovarian steroids have widespread effects throughout the brain, including brain stem and midbrain catecholaminergic neurons, midbrain serotonergic pathways, midbrain dopaminergic activity, and the basal forebrain cholinergic system (see Table 2). Whereas basal forebrain cholinergic function is involved in attention, noradrenergic function is involved in arousal, serotonin is involved with mood and affect, and dopamine is involved with reward (2). Regulation of the serotonergic system appears to be mediated in part by the presence of estrogen- and progestin-sensitive neurons in the midbrain raphe and leads to the induction of tryptophan hydroxylase and the regulation of serotonin CLINICAL REVIEW transporters and serotonergic receptor subtypes (37), whereas the ovarian steroid influence on cholinergic function occurs in basal forebrain neurons that express intracellular ER and leads to the induction of choline acetyltransferase and acetylcholinesterase according to a sexually dimorphic pattern (38, 39). Noradrenergic and dopaminergic systems also show sex differences and both direct and indirect effects of estrogens via conventional ER and by nongenomic mechanisms. Because of the widespread projections of these systems in the forebrain, these various neuronal systems have important global effects on arousal and attentional mechanisms as well as more specific actions related to learning and remembering, particularly of verbal information. Thus, it is not so surprising that ovarian steroids have measurable effects on those aspects of cognition and also on mood and affect and motor coordination; these effects are evident after ovariectomy and during the decline of estrogens that occurs after the menopause and with aging (2). However, as noted above, one of the fundamental questions is the mechanism by which these effects occur, whether by traditional intracellular receptors or by the novel, nongenomic mechanisms that are referred to above, and as noted, we have seen that the diversity of mechanisms and uncertainties about receptor identity leave us still somewhat in the dark about the exact molecular events. Fourth, estrogen effects on memory have been reported in animal models and in studies on humans (2). The memories affected are ones in which the hippocampus plays a role along with the basal forebrain cholinergic system; in rats, the sensitive memories are related to spatial information (40 – 43), whereas in humans, it is verbal memory that is particularly sensitive (44 – 46). Yet, there is some contradiction in terms of the time course of the effects and the types of memory affected between the reported estrogen actions and the known cellular processes, such as estrogen-induced synaptogenesis. For example, estrogen-induced synaptogenesis in the rat hippocampus occurs within several days, yet the effects of estrogen on cognitive function in rats and humans noted above take a number of weeks to be fully manifested. Moreover, the more rapid actions of estrogens in both rats and humans (i.e. over the time course of a few days) seem to be associated with impairment of spatial memory (47, 48). Thus, much more research is needed to reconcile morphological and neurochemical changes with the behavioral data. It cannot be overemphasized that rather than one estrogenregulated process or one brain region, many types of estrogen action on a number of neurochemical and neuroanatomical substrates and a number of molecular mechanisms are likely to underlie the actions of estrogens on cognition and other aspects of behavior, such as mood, pain perception, and nociception. Estrogens and neuroprotection in relation to aging and dementia There is growing evidence that estrogens not only have reversible effects to improve memory, affect, and motor coordination in women who suffer from estrogen deficiency after the menopause, but they also appear to have a neuroprotective effect for Alzheimer’s disease and protect cells 1795 from damage and destruction by free radicals and b-amyloid protein. Moreover, the cognitive improvement seen in Alzheimer’s disease patients after treatment with the cholinesterase blocker, tacrine, is reported to be most evident in women also receiving ERT (49). There are at least two ways in which estrogens appear to be able to protect the brain from neurodegeneration. First, as discussed above and summarized in Table 2, estrogens maintain function of key neural structures, such as the hippocampus and basal forebrain, and the widely projecting dopaminergic, serotonergic, and noradrenergic systems. As estrogen levels decline over the menopause, these systems and the cognitive and other behavioral processes that depend upon them also decline, as least functionally; yet, they appear to respond to estrogen replacement. It is conceivable that estrogens not only maintain function but also confer resilience against neural damage by various agents due to their ability to maintain synaptic connections and promote the activities of these important neural systems. The second type of neuroprotective effect of estrogens is a more direct involvement in blocking the actions of neurotoxic agents or inhibiting their generation. As noted above and in Table 1, the A ring of the estrogen molecule appears to have special properties with respect to the formation of free radicals and special protective effects on cells in culture that are deprived of serum or exposed to free radical generators (2). In this regard, in vivo studies of estrogen-mediated neuroprotection have reported successful reduction of lesion size by SILASTIC brand implants (Dow Corning Corp., Midland, MI) of 17b-estradiol in male rats subjected to middle cerebral artery occlusion (50). In another study, a single injection of 17b-estradiol reduced damage to hilar neurons in the hippocampal dentate gyrus of female rats caused by kainic acid treatment (51). In addition, estrogen treatment of cultured nerve decreases formation of the toxic form of the b-amyloid protein (52). Moreover, estrogen treatment interferes with the toxic effects of the b-amyloid protein (53) and the human immunodeficiency virus coat protein, gp120 (54), both of which act via free radical generation. Besides neurons, the glial cells of the brain are implicated in aspects of oxidative energy metabolism, brain plasticity, brain aging, and neuroprotection (see Ref. 2 for more details). Glial cells and vascular epithelium play a role in the adult brain in relation to glucose uptake and energy metabolism, and ovarian steroids regulate the ability of the female brain to use glucose as its primary energy source. For example, in studies of postmenopausal women with or without ERT, there were significant enhancing effects of estrogen on verbal and figural memory tests as well as enhancements of cerebral blood flow during the memory tasks (55). Moreover, glial cells are affected by estrogens in vivo and in vitro, and they express a number of proteins that are regulated by estrogens, including apolipoprotein E and glial fibrillary acidic protein; apolipoprotein E is implicated in membrane formation and structural plasticity, whereas glial fibrillary acidic protein expression increases throughout the brain as it ages (2, 56). Astroglia play a role in synaptic retraction during the ovulatory cycle in the adult hypothalamic arcuate nucleus. During the preovulatory and ovulatory phases of the female rat estrous cycle, there is a transient disconnection of inhibitory 1796 MCEWEN synaptic inputs to arcuate nucleus neurons, and this remodeling is mediated in part by soluble factors, such as insulinlike growth factor I (IGF-I) (57). Moreover, there seems to be a reciprocal interaction between IGF-I and estrogen, and one speculation is that estrogens may act in arcuate nucleus neurons to regulate the production of a factor, possibly g-aminobutyric acid that, in turn, regulates the expression of IGF-I by astroglia (tanycytes) in the arcuate nucleus region (57). The mechanisms of estrogen action on glial cell function remain unclear, but they may involve some limited expression of both ERa and ERb within astrocytes, oligodendrocytes, and/or microglia (2). 11. 12. 13. 14. 15. 16. Conclusions Many regions of the central nervous system respond to estrogens, and we are rapidly gaining insights into their diverse cellular and molecular mechanisms of action. Although there is no proof at this time that estrogens are truly neuroprotective and capable of slowing down Alzheimer’s disease, they are perhaps the most promising agents yet devised for this purpose. ERT is already strongly supported as therpay for osteoporosis and cardiovascular protection, and protection of the brain, along with benefits in terms of memory, motor coordination, and affect, would add additional reasons for using ERT. The question of whether males would also benefit from ERT is also very important, but to date has not been adequately explored. Likewise, the actions of androgens on the male brain deserve much more study, particularly with regard to possible neuroprotection as well as beneficial neurocognitive effects. Sex differences in the brain do not preclude the efficacy of ERT in males, but they do indicate the need for careful and systematic studies of estrogen actions in men as well as women. The development of novel compounds with specific estrogenic activities, such as the selective estrogen response modulators, offers new hope for benefiting both men and women. However, based upon the diversity of sites and molecular mechanisms of action of estrogens in the brain, each novel compound needs to be carefully evaluated in terms of what it does to a variety of neural estrogen effects in the central nervous system. References 1. Pfaff DW. 1980 Estrogens and brain function. New York: Springer-Verlag. 2. McEwen BS, Alves SH. 1999 Estrogen actions in the central nervous system. Endocr Rev. 20:278 –306. 3. Jensen E, Jacobson H. 1962 Basic guides to the mechanism of estrogen action. Recent Prog Horm Res. 18:387– 408. 4. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson J. 1996 Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA. 93:5925–5930. 5. Tremblay GB, Tremblay A, Copeland NG, Gilbert DJ, Jenkins NA, Labrie F, Giguere V. 1997 Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor b. Mol Endocrinol. 11:353–365. 6. Pettersson K, Grandien K, Kuiper GGJM, Gustafsson J. 1997 Mouse estrogen receptor b forms estrogen response element-binding heterodimers with estrogen receptor a. Mol Endocrinol. 11:1486 –1496. 7. Korach KS. 1994 Insights from the study of animals lacking functional estrogen receptor. Science. 266:1524 –1527. 8. Smith EP, Boyd J, Frank GR, et al. 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 331:1056 –1061. 9. Krege JH, Hodgin JB, Couse JF, et al. 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor b. Proc Natl Acad Sci USA. 95:15677–15682. 10. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. 38. 39. JCE & M • 1999 Vol 84 • No 6 Gustafsson J. 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology. 138:863– 870. Chu S, Fuller PJ. 1997 Identification of a splice variant of the rat estrogen receptor b gene. Mol Cell Endocrinol. 132:195–199. Maruyama K, Endoh H, Sasaki-Iwaoka H, et al. 1998 A novel isoform of rat estrogen receptor beta with 18 amino acid insertion in the ligand binding domain as a putative dominant negative regular of estrogen action. Biochem Biophys Res Commun. 246:142–147. Pfaff DW, Keiner M. 1973 Atlas of estradiol-concentrating cells in the central nervous system of the female rat. J Comp Neurol. 151:121–158. Stumpf WE, Sar M. 1976 Steroid hormone target sites in the brain: the differential distribution of estrogen, progestin, androgen and glucocorticosteroid. J Steroid Biochem. 7:1163–1170. Shughrue PJ, Lane MV, Merchenthaler I. 1997 Comparative distribution of estrogen receptor-a and -b mRNA in the rat central nervous system. J Comp Neurol. 388:507–525. Kuiper GGJM, Shughrue PJ, Merchenthaler I, Gustafsson J-A. 1998 The estrogen receptor b subtype: a novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol. 19:253–286. Paech K, Webb P, Kuiper GGJM, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS. 1997 Differential ligand activation of estrogen receptors ERa and ERb at AP1 sites. Science. 277:1508 –1510. Hrabovszky E, Kallo I, Hajszan T, Shughrue PJ, Merchenthaler I, Liposits Z. 1998 Expression of estrogen receptor-b messenger ribonucleic acid in oxytocin and vasopressin neurons of the rat supraoptic and paraventricular nuclei. Endocrinology. 139:2600 –2604. Roy E, MacLusky N, McEwen BS. 1979 Antiestrogen inhibits the induction of progestin receptors by estradiol in the hypothalamus, pituitary and uterus. Endocrinology. 104:1333–1336. Meisel R, Dohanich G, McEwen BS, Pfaff DW. 1987 Antagonism of sexual behavior in female rats by ventromedial hypothalamic implants of antiestrogen. Neuroendocrinology. 45:201–207. Luine V, McEwen BS. 1977 Effects of an estrogen antagonist on enzyme activities and 3H estradiol nuclear binding in uterus, pituitary and brain. Endocrinology. 100:903–910. McEwen BS, Tanapat P, Weiland NG. 1999 Inhibition of dendritic spine induction on hippocampal CA1 pyramidal neurons by a non-steroidal estrogen antagonist in female rats. Endocrinology. 140:1044 –1047. Watson CS, Pappas TC, Gametchu B. 1995 The other estrogen receptor in the plasma membrane: implications for the actions of environmental estrogens. Environ Health Perspect. 103:41–50. Razandi M, Pedram A, Greene GL, Levin ER. 1999 Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERa and ERb expressed in Chinese hamster ovary cells. Mol Endocrinol. 13:307–319. Zhou Y, Watters JJ, Dorsa DM. 1997 Estrogen rapidly induces the phosphorylation of the cAMP response element binding protein in rat brain. Endocrinology. 137:2163–2166. Gu G, Rojo AA, Zee MC, Yu J, Simerly RD. 1996 Hormonal regulation of CREB phosphorylation in the anteroventral periventricular nucleus. J Neurosci. 16:3035–3044. Singh M, Setalo GJ, Guan X, Warren M, Toran-Allerand CD. 1999 Estrogeninduced activation of mitogen-activated protein kinase in cerebral cortical explants: convergence of estrogen and neurotrophin signaling pathways. J Neurosci. 19:1179 –1188. Goy R, McEwen BS. 1980 Sexual differentiation of the brain. Cambridge: MIT Press. Naftolin F. 1994 Brain aromatization of androgens. J Reprod Med. 39:257–261. Woolley C, McEwen BS. 1993 Roles of estradiol and progesterone in regulation of hippocampal dendritic spine density during the estrous cycle in the rat. J Comp Neurol. 336:293–306. Woolley C, McEwen BS. 1994 Estradiol regulates hippocampal dendritic spine density via an N-methyl-d-aspartate receptor dependent mechanism. J Neurosci. 14:7680 –7687. Kimura D. 1992 Sex differences in the brain. Sci Am. 267:119 –125. O’Keefe JA, Handa RJ. 1990 Transient elevation of estrogen receptors in the neonatal rat hippocampus. Dev Brain Res. 57:119 –127. MacLusky N, Clark AS, Naftolin F, Goldman-Rakic PS. 1987 Oestrogen formation in the mammalian brain: possible role of aromatase in sexual differentiation of the hippocampus and neocortex. Steroids. 50:459 – 474. Williams CL, Meck WH. 1991 The organizational effects of gonadal steroids on sexually dimorphic spatial ability. Psychoneuroendocrinology. 16:155–176. Lewis C, McEwen BS, Frankfurt M. 1995 Estrogen-induction of dendritic spines in ventromedial hypothalamus and hippocampus: effects of neonatal aromatase blockade and adult castration. Dev Brain Res. 87:91–95. Bethea CL, Pecins-Thompson M, Schutzer WE, Gundlah C, Lu ZN. 1999 Ovarian steroids and serotonin neural function. Mol Neurobiol. 18:87–123. Luine V, Renner K, McEwen BS. 1986 Sex-dependent differences in estrogen regulation of choline acetyltransferase are altered by neonatal treatments. Endocrinology. 119:874 – 878. Gibbs RB, Aggarwal P. 1998 Estrogen and basal forebrain cholinergic neurons: CLINICAL REVIEW 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. implications for brain aging and Alzheimer’s disease-related cognitive decline. Horm Behav. 34:98 –111. O’Neal MF, Means LW, Poole MC, Hamm RJ. 1996 Estrogen affects performance of ovariectomized rats In a two-choice water-escape working memory task. Psychoneuroendocrinology. 21:51– 65. Daniel JM, Fader AJ, Spencer AL, Dohanich GP. 1997 Estrogen enhances performance of female rats during acquisition of a radial arm maze. Horm Behav. 32:217–225. Luine VN, Richards ST, Wu VY, Beck KD. 1998 Estradiol enhances learning and memory in a spatial memory task and effects levels of monoaminergic neurotransmitters. Horm Behav. 34:149 –162. Juraska JM, Warren SG. 1996 Spatial memory decline in aged, non-cycling female rats varies with the phase of estropause [Abstract 547.12] Soc Neurosci Abstr. 22:1387. Sherwin BB. 1994 Estrogenic effects on memory in women. Ann NY Acad Sci. 743:213–231. Robinson D, Friedman L, Marcus R, Tinklenberg J, Yesavage J. 1994 Estrogen replacement therapy and memory in older women. J Am Geriatr Soc. 42:919 –922. Sherwin BB, Tulandi T. 1996 “Add-back” estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab. 81:2545–2549. Frye CA. 1995 Estrus-associated decrements in a water maze task are limited to acquisition. Physiol Behav. 57:5–14. Kimura D. 1996 Sex, sexual orientation and sex hormones influence human cognitive function. Curr Option Neurobiol. 6:259 –263. Schneider LS, Farlow MR, Henderson VW, Pogoda JM. 1996 Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer’s disease. Neurology. 46:1580 –1584. Hawk T, Zhang Y, Rajakumar G, Day AL, Simpkins JW. 1998 Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res. 796:296 –298. Azcoitia I, Sierra A, Garcia-Segura LM. 1998 Estradiol prevents kainic acidinduced neuronal loss in the rat dentate gyrus. NeuroReport. 9:3075–3079. Xu H, Gouras GK, Greenfield JP, et al. 1998 Estrogen reduces neuronal generation of Alzheimer b-amyloid peptides. Nat Med. 4:447– 451. Goodman Y, Bruce AJ, Cheng B, Mattson MP. 1996 Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid b-peptide toxicity in hippocampal neurons. J Neurochem. 66:1836 –1844. Brooke S, Chan R, Howard S, Sapolsky R. 1997 Endocrine modulation of the neurotoxicity of gp120:implications for AIDS-related dementia complex. Proc Natl Acad Sci USA. 94:9457–9462. Resnick SM, Maki PM, Golski S, Kraut MA, Zonderman AB. 1998 Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm Behav. 34:171–182. Schipper HM. 1996 Astrocytes, brain aging, and neurodegeneration. Neurobiol Aging. 17:467– 480. Fernandez-Galaz MC, Morschl E, Chowen JA, Torres-Aleman I, Naftolin F, Garcia-Segura LM. 1997 Role of astroglia and insulin-like growth factor-1 in gonadal hormone-dependent synaptic plasticity. Brain Res Bull. 44:525–531. Boyle M, MacLusky N, Naftolin F, Kaczmarek L. 1987 Hormonal regulation of K1-channel messenger RNA in rat myometrium during oestrus cycle and in pregnancy. Nature. 330:373–375. Joels M, Karst H. 1995 Effects of estradiol and progesterone on voltage-gated calcium and potassium conductances in rAt CA1 hippocampal neurons. J Neurosci. 15:4289 – 4297. Gu Q, Korach KS, Moss RL. 1999 Rapid action of 17b-estradiol on kainateinduced currents in hippocampal neurons lacking intracellular estrogen receptors. Endocrinology. 140:660 – 666. Mermelstein PG, Becker JB, Surmeier DJ. 1996 Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J Neurosci. 16:595– 604. Morley P, Whitfield JF, Vanderhyden BC, Tsang BK, Schwartz J-L. 1992 A new, nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology. 131:1305–1312. Green PS, Gridley KE, Simpkins JW. 1996 Estradiol protects against b-amyloid (25–35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett. 218:165–168. Singer CA, Rogers KL, Stickland TM, Dorsa DM. 1996 Estrogen protects primary cortical neurons from glutamate toxicity. Neurosci Lett. 212:13–16. 1797 65. Schneider LS, Small GW, Hamilton SH, Bystritsky A, Nemeroff CB, Meyers BS. 1997 Estrogen replacement and the response to fluoxetine in a multicenter geriatric depression trial. Am J Geriatr Psychiatry. 5:97–106. 66. Tseng JY, Kolb PE, Raskind MA, Miller MA. 1997 Estrogen regulates galanin but not tyrosine hydroxylase gene expression in the rat locus coeruleus. Mol Brain Res. 50:100 –106. 67. Murphy DD, Segal M. 1996 Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J Neurosci. 16:4059 – 4068. 68. Murphy DD, Segal M. 1997 Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci USA. 94:1482–1487. 69. Murphy DD, Cole NB, Greenberger V, Segal M. 1998 Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci. 18:2550 –2559. 70. Murphy DD, Cole NB, Segal M. 1998 Brain-derived neurotrophic factor mediates estradiol-induced dendritic spine formation in hippocampal neurons. Proc Natl Acad Sci USA. 95:11412–11417. 71. Amandusson A, Hermanson O, Blomqvist A. 1996 Colocalization of oestrogen receptor immunoreactivity and preproenkephalin mRNA expression to neurons in the superficial laminae of the spinal and medullary dorsal horn of rats. Eur J Neurosci. 8:2440 –2445. 72. Purcell R, Maruff P, Kyrios M, Pantelis C. 1998 Cognitive deficits in obsessivecompulsive disorder on tests of frontal-striatal function. Biol Psychiatry. 43:348 –357. 73. Mogil JS, Sternberg WF, Kest B, Marek P, Liebeskind JC. 1993 Sex differences in the antagonism of swim stres-induced analgesia: effects of gonadectomy and estrogen replacement. Pain. 53:17–25. 74. Mogil JS, Richards SP, O’Toole LA, Helms ML, Mitchell SR, Kest B, Belknap JK. 1997 Identification of a sex-specific quantitative trait locus mediating nonopioid stress-induced analgesia in female mice. J Neurosci. 17:7995– 8002. 75. Sternberg WF, Mogil JS, Kest B, Page GG, Leong Y, Yam V, Liebeskind JC. 1996 Neonatal testosterone exposure influences neurochemistry of swim stress-induced analgesia in adult mice. Pain. 63:321–326. 76. Langub MC, Watson RE. 1992 Estrogen receptor-immunoreactive glia, endothelia, and ependyma in guinea pig preoptic area and median eminence: electron microscopy. Endocrinology. 130:364 –372. 77. Shi J, Simpkins JW. 1997 17b-Estradiol modulation of glucose transporter 1 expression in blood-brain barrier. Am J Physiol 272:E1016 –E1022. 78. Rubinow DR. 1992 The premenstrual syndrome: new views. JAMA. 268:1908 –1912. 79. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. 1998 Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 338:209 –216. 80. Klaiber EL, Brovermann DM, Vogel W, Peterson LG, Snyder MB. 1996 Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroendocrinology. 21:575–592. 81. Kendall DA, Stancel GM, Enna SJ. 1982 The influence of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J Neurosci. 2:354 –360. 82. Fillit H, Weinreb H, Cholst I, Luine V, McEwen BS, Amador R, Zabriskie J. 1986 Observations in a preliminary open trial of estradiol therapy for senile dementia–Alzheimer’s type. Psychoneuroendocrinology. 11:337–345. 83. Resnick SM, Metter EJ, Zonderman AB. 1997 Estrogen replacement therapy and longitudinal decline in visual memory: a possible protective effect? Neurology. 49:1491–1497. 84. Jacobs DM, Tang M-X, Stern Y, et al. 1998 Cognitive function in nondemented older women who took estrogen after menopause. Neurology. 50:368 –373. 85. Paganini-Hill A, Henderson VW. 1994 Estrogen deficiency and risk of Alzheimer’s disease in women. Am J Epidemil. 3:3–16. 86. Tang MX, Jacobs D, Stern Y, et al. 1996 Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet. 348:429 – 432. 87. Bonuccelli U, Melis GB, Paoletti AM, Fioretti P, Murri L, Muratoria A. 1989 Unbalanced progesterone and estradiol secretion in catamenial epilepsy. Epilepsy Res. 3:100 –1006. 88. Herzog AG. 1991 Reproductive endocrine considerations and hormonal therapy for women with epilepsy. Epilepsy 62:S27–S33. 89. McEwen BS. 1994 Ovarian steroids have diverse effects on brain structure and function. In: Berg G, Hammar M, eds. The modern management of the menopause. New York: Parthenon; 269 –278.